Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials.
Popejoy MW, Paterson DL, Cloutier D, Huntington JA, Miller B, Bliss CA, Steenbergen JN, Hershberger E, Umeh O, Kaye KS. Popejoy MW, et al. Among authors: steenbergen jn. J Antimicrob Chemother. 2017 Jan;72(1):268-272. doi: 10.1093/jac/dkw374. Epub 2016 Oct 5. J Antimicrob Chemother. 2017. PMID: 27707990 Clinical Trial.
Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model.
VanScoy B, Mendes RE, Nicasio AM, Castanheira M, Bulik CC, Okusanya OO, Bhavnani SM, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG. VanScoy B, et al. Among authors: steenbergen jn. Antimicrob Agents Chemother. 2013 Jun;57(6):2809-14. doi: 10.1128/AAC.02513-12. Epub 2013 Apr 29. Antimicrob Agents Chemother. 2013. PMID: 23629705 Free PMC article.
Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections.
Lucasti C, Hershberger E, Miller B, Yankelev S, Steenbergen J, Friedland I, Solomkin J. Lucasti C, et al. Antimicrob Agents Chemother. 2014 Sep;58(9):5350-7. doi: 10.1128/AAC.00049-14. Epub 2014 Jun 30. Antimicrob Agents Chemother. 2014. PMID: 24982069 Free PMC article. Clinical Trial.
Relationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection model.
VanScoy BD, Mendes RE, Castanheira M, McCauley J, Bhavnani SM, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG. VanScoy BD, et al. Among authors: steenbergen jn. Antimicrob Agents Chemother. 2014 Oct;58(10):6024-31. doi: 10.1128/AAC.02310-13. Epub 2014 Jul 28. Antimicrob Agents Chemother. 2014. PMID: 25070105 Free PMC article.
Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).
Solomkin J, Hershberger E, Miller B, Popejoy M, Friedland I, Steenbergen J, Yoon M, Collins S, Yuan G, Barie PS, Eckmann C. Solomkin J, et al. Clin Infect Dis. 2015 May 15;60(10):1462-71. doi: 10.1093/cid/civ097. Epub 2015 Feb 10. Clin Infect Dis. 2015. PMID: 25670823 Free PMC article. Clinical Trial.
Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor Combinations.
Soon RL, Lenhard JR, Bulman ZP, Holden PN, Kelchlin P, Steenbergen JN, Friedrich LV, Forrest A, Tsuji BT. Soon RL, et al. Among authors: steenbergen jn. Antimicrob Agents Chemother. 2016 Mar 25;60(4):1967-73. doi: 10.1128/AAC.02635-15. Print 2016 Apr. Antimicrob Agents Chemother. 2016. PMID: 26729494 Free PMC article.
58 results